BETA

8 Amendments of Andreas GLÜCK related to 2023/2081(INI)

Amendment 44 #
Motion for a resolution
Recital I a (new)
Ia. whereas, in 2020, the Commissions concluded in its evaluation1a that consumers continue to be exposed to unsubstantiated health claims from the on-hold list and may believe that the beneficial effects communicated with the on-hold claims have been scientifically assessed and risk managed, whilst this is not the case; _________________ 1a https://food.ec.europa.eu/system/files/202 0-05/labelling_nutrition- claims_swd_2020-96_sum_en.pdf
2023/10/16
Committee: ENVI
Amendment 45 #
Motion for a resolution
Recital J
J. whereas consumers are thuscontinue to be exposed to health claims with varying levels of scientific assessment, including claims that have yet to be authorised on botanical products or even failed to provide sufficient data to reach a conclusion about the cause- and-effect relationship;
2023/10/16
Committee: ENVI
Amendment 51 #
Motion for a resolution
Recital L
L. whereas herbal medicines must undergo authorisation procedures before their introduction to the EU market, necessitating the demonstration of product safety, quality and efficacy; whereas herbal medicines which are intended for the use without the supervision of a medical practitioner, that have been safely used for 30 years, including 15 years in the EU, can use a simplified registration procedure for traditional herbal medicinal products, where ‘traditional use’ data is accepted to substantidemonstrate the safety and efficacy of the product;
2023/10/16
Committee: ENVI
Amendment 85 #
Motion for a resolution
Paragraph 6
6. Highlights that consumers tend to overconsume food products bearing claims to promote better health, which is known as the ‘halo-effect’; advocates for the inclusion of both minimum and maximum usage thresholds on product labels, along with a recommendation to consult a healthcare professional before consuming food supplements in order to avoid potential adverse interactions with specific treatments;deleted
2023/10/16
Committee: ENVI
Amendment 113 #
Motion for a resolution
Paragraph 11
11. Considers it appropriate to explore the concept of ‘traditional use data’ in the efficacy assessment of health claims on plants used in food, taking into account the current regime for traditional herbal medicinal products; invites the Commission to assess whether the acceptance of traditional use evidence for the efficacy substantiation of health claims on botanicals would necessitate the creation of a separate category within the NHCR;deleted
2023/10/16
Committee: ENVI
Amendment 114 #
Motion for a resolution
Paragraph 11 a (new)
11a. Points out that it is not always obvious for consumers to distinguish between traditional herbal medicinal products and foods with health claims, which can lead to misunderstandings about their use; simply extending the concept of 'traditional use data' for the classification of health claims on plants used in food, which currently applies only to traditional herbal medicines that must meet clear legal criteria indicating medicinal use, would be inappropriate and would only exacerbate the problem of misled consumers;
2023/10/16
Committee: ENVI
Amendment 115 #
Motion for a resolution
Paragraph 11 a (new)
11a. Considers it essential to promptly review, in line with the provisions of Regulation (EC) No 1924/2006, the yet-to- be-assessed health claims related to botanicals in foods, especially for claims currently on the 'on hold list', ensuring the rejection of any previously negatively assessed claims to guarantee consumer protection;
2023/10/16
Committee: ENVI
Amendment 116 #
Motion for a resolution
Paragraph 12
12. Underlines that regulatory changes regarding the substantiation of claims on botanicals would need to be accompanied by the harmonisation of the safety framework for botanicals; emphasises the key importance of safety in use and advocates for regular reviews to be performed if claims were to be authorised based on ‘traditional use data’; insists on mandatory product labelling indicating claims authorised based on ‘traditional use data’ and advising that a physician should be consulted to ensure safe use and to avoid interactions with existing treatments or medical conditions;deleted
2023/10/16
Committee: ENVI